Pulmonx (Pulmonx) 3-Year Revenue Growth Rate : -17.40% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx 3-Year Revenue Growth Rate?

Pulmonx's Revenue per Share for the three months ended in Dec. 2023 was $0.50.

During the past 12 months, Pulmonx's average Revenue per Share Growth Rate was 24.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -17.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Pulmonx was 11.50% per year. The lowest was -17.40% per year. And the median was -2.80% per year.

Competitive Comparison of Pulmonx's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Pulmonx's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulmonx's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Pulmonx's 3-Year Revenue Growth Rate falls into.

Pulmonx 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Pulmonx (NAS:LUNG) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Pulmonx 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Pulmonx's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx (Pulmonx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

4NI:Germany

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Executives

French Glendon E. Iii	director, officer: President and CEO	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose	officer: Chief Commercial Officer	5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune	officer: Interim CFO	46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung	officer: Chief Financial Officer	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp	10 percent owner	300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin	director	56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns	director	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou	director	C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51